LinkedIn facebook twitter youtube
News archive
Recent news


As part of the CARAMBA consortium, Myeloma Patients Europe (MPE) has developed an information sheet to explain the main goals and characteristics of the CARAMBA clinical trial investigating SLAMF7 chimeric antigen receptor T-cell (CAR-T) therapy. This publication discusses some potential CAR-T side effects and considerations for patients and caregivers. This information sheet has been previously published on our website in English and is now available in four additional languages: French, Italian, Spanish and German.


CARAMBA is a Horizon 2020 project investigating innovative immunotherapy to treat myeloma called SLAMF7 CAR-T therapy. CAR-T is a form of immunotherapy that has demonstrated outstanding efficacy against various haematologic malignancies.


The CARAMBA clinical trial will take place in four centres of excellence in myeloma clinical care and research: University Hospital Würzburg (Germany), Ospedale San Raffaele (Italy), Universidad de Navarra (Spain) and the Centre Hospitalier Regional et Universitaire de Lille (France). Although each of the four clinical trial sites may begin enrolment at different times, the opening of the CARAMBA clinical trial was in August of 2020.

Click below for your preferred language to find the full CARAMBA Myeloma Pipeline information sheet:


For further information about Horizon2020 CARMABA, please visit: https://www.caramba-cart.eu/


Recent news

» Melflufen receives positive opinion from the European Medicines Agency (EMA) for the treatment of refractory myeloma

» EHA 2022 highlights in myeloma and AL amyloidosis

Leave a Reply

Your email address will not be published.

I accept the Privacy Policy